Jon Congleton sold $530K of Mineralys Therapeutics (MLYS)

Executed Jan 12, disclosed Jan 13, 1 day later.

Value, as filed

$530K

16,236 sh across 2 lots

Executed

Jan 12

the trade date, as filed

Disclosed

Jan 13

1 day after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

JC Jon Congleton Chief Executive Officer profile →

Jon Congleton (Chief Executive Officer) filed 7 Form 4 reports in the trailing twelve months (0 purchases, 7 sales), most often in Mineralys Therapeutics, Inc. (MLYS). The largest single filing was $9.1M of MLYS (200,000 sh across 6 lots, as filed), executed Nov 11 2025.

The name

MLYS Mineralys Therapeutics, Inc. MLYS · Healthcare · 50 filings in 24 months ticker →

Healthcare · Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Jon Congleton in MLYS

MLYSSALE Mineralys Therapeutics, Inc. $291K
10,700 sh × $27.24
Exec Jul 13
Filed Jul 15 · 8:58 PM ET MLYSSALE Mineralys Therapeutics, Inc. $2.0M
75,000 sh across 2 lots
Exec Jun 30
Filed Jun 30 · 5:30 PM ET MLYSSALE Mineralys Therapeutics, Inc. $422K
15,730 sh × $26.83
Exec Apr 13
Filed Apr 15 · 5:30 PM ET MLYSSALE Mineralys Therapeutics, Inc. $2.0M
74,547 sh across 2 lots
Exec Mar 31
Filed Apr 2 · 5:30 PM ET MLYSSALE Mineralys Therapeutics, Inc. $9.1M
200,000 sh across 6 lots
Exec Nov 11 2025
Filed Nov 13 2025 · 5:30 PM ET MLYSSALE Mineralys Therapeutics, Inc. $578K
13,548 sh × $42.63
Exec Oct 13 2025
Filed Oct 15 2025 · 5:30 PM ET MLYSSALE Mineralys Therapeutics, Inc. $230K
15,884 sh × $14.51
Exec Jul 11 2025
Filed Jul 15 2025 · 5:30 PM ET MLYSSALE Mineralys Therapeutics, Inc. $187K
15,319 sh × $12.19
Exec Apr 11 2025
Filed Apr 15 2025 · 5:30 PM ET